Evaluation of Collimators in a High-Resolution, Whole-Body SPECT/CT Device with a Dual-Head Cadmium-Zinc-Telluride Detector for 123I-FP-CIT SPECT.

The study aim was to evaluate the adaptation of collimators to 123I-N-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl)nortropane (123I-FP-CIT) dopamine transporter SPECT (DAT-SPECT) by a high-resolution whole-body SPECT/CT system with a cadmium-zinc-telluride detector (C-SPECT) in terms of image quality, quantitation, diagnostic performance, and acquisition time. Methods: Using a C-SPECT device equipped with a wide-energy, high-resolution collimator and a medium-energy, high-resolution sensitivity (MEHRS) collimator, we evaluated the image quality and quantification of DAT-SPECT for an anthropomorphic striatal phantom. Ordered-subset expectation maximization iterative reconstruction with resolution recovery, scatter, and attenuation correction was used, and the optimal collimator was determined on the basis of the contrast-to-noise ratio (CNR), percentage contrast, and specific binding ratio. The acquisition time that could be reduced using the optimal collimator was determined. The optimal collimator was used to retrospectively evaluate diagnostic accuracy via receiver-operating-characteristic analysis and specific binding ratios for 41 consecutive patients who underwent DAT-SPECT. Results: When the collimators were compared in the phantom verification, the CNR and percentage contrast were significantly higher for the MEHRS collimator than for the wide-energy high-resolution collimator (P < 0.05). There was no significant difference in the CNR between 30 and 15 min of imaging time using the MEHRS collimator. In the clinical study, the areas under the curve for acquisition times of 30 and 15 min were 0.927 and 0.906, respectively, and the diagnostic accuracies of the DAT-SPECT images did not significantly differ between the 2 times. Conclusion: The MEHRS collimator provided the best results for DAT-SPECT with C-SPECT; shorter acquisition times (<15 min) may be possible with injected activity of 167-186 MBq.

Verification of phantom accuracy using a Monte Carlo simulation: bone scintigraphy chest phantom.

We aimed to compare the measurement and simulation data of bone scintigraphy of a chest phantom using a Monte Carlo simulation to verify the accuracy of the simulated data. The SIM2 bone phantom was enclosed using 300 kBq/mL of technetium-99 m (99mTc) to represent the bone tumor and 50 kBq/mL of 99mTc to represent normal bone. Projection data were obtained using single-photon emission computed tomography (SPECT). Simulated projection data were constructed based on CT data. The contrast ratio, recovery coefficient (RC), % coefficient variation (CV), and power spectrum density (PSD) of each part were calculated from the reconstructed data. The contrast ratio and RC were equal between the actual and simulated data. Higher % CV values were noted for soft tissue than for normal bone. The PSD was equal for all frequency band ranges. Our results prove the utility of the Monte Carlo simulation for verifying various data using phantoms.